Russia's RDIF to sell 32 mln COVID-19 vaccine doses to Mexico firm - source
Late-stage trials of Sputnik-V, due to involve 40,000 participants, were launched on Aug. 26. The Russian Direct Investment Fund (RDIF), the state sovereign wealth fund backing the vaccine's development, signed its first export deal with Kazakhstan in August.
- Country:
- Russia
Russia's sovereign wealth fund will sell 32 million doses of potential COVID-19 vaccine 'Sputnik-V' to a top pharmaceutical company in Mexico, Russia's second vaccine export deal, a source close to the deal said on Wednesday. Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute, in August. Late-stage trials of Sputnik-V, due to involve 40,000 participants, were launched on Aug. 26.
The Russian Direct Investment Fund (RDIF), the state sovereign wealth fund backing the vaccine's development, signed its first export deal with Kazakhstan in August. Kazakhstan is set to buy more than 2 million doses initially and could later increase the volume to 5 million doses, RDIF said at the time. pin
The deal with Mexico is expected to be announced later on Wednesday, the source said.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Floods swamp swathes of Russia and Kazakhstan but worse still to come
Biden and Japan's Kishida forge new partnership, eyeing China and Russia
Russia intensifies crackdown on dissent by placing additional Kremlin critics on wanted list
Russia launches 'counter-terrorist operation' in southern region, RIA reports
Water levels rise in Russian rivers in flooding zone